Browsing Molecular Pathology by author "Hahne, Jens"
Now showing items 1-20 of 31
-
A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.
Smyth, EC; Nyamundanda, G; Cunningham, D; Fontana, E; Ragulan, C; et al. (OXFORD UNIV PRESS, 2018-12-01)BACKGROUND: Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only validated prognostic variable; however, within lymph node groups there is still heterogeneity with risk ... -
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.
Mensah, AA; Cascione, L; Gaudio, E; Tarantelli, C; Bomben, R; et al. (FERRATA STORTI FOUNDATION, 2018-11-30)Aberrant changes in microRNA expression contribute to lymphomagenesis. Bromodomain and extra-terminal domain inhibitors such as OTX015 (MK-8628, birabresib) have demonstrated preclinical and clinical activity in hematologic ... -
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.
Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; et al. (2017-06)Background Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but ... -
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.
Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; et al. (OXFORD UNIV PRESS, 2017-02-23)BACKGROUND: Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but ... -
Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review).
Lampis, A; Ratti, M; Ghidini, M; Mirchev, MB; Okuducu, AF; et al. (SPANDIDOS PUBL LTD, 2021-06-01)Oesophageal cancer is one of the most aggressive malignancies with limited treatment options, thus resulting in a high morbidity and mortality. With 5‑year survival rates of only 5‑10%, oesophageal cancer holds a dismal ... -
Characterisation of the immune-related transcriptome in resected biliary tract cancers.
Ghidini, M; Cascione, L; Carotenuto, P; Lampis, A; Trevisani, F; et al. (ELSEVIER SCI LTD, 2017-11-01)UNLABELLED: Although biliary tract cancers (BTCs) are known to have an inflammatory component, a detailed characterisation of immune-related transcripts has never been performed. In these studies, nCounter PanCancer Immune ... -
Circulating Tumour DNAs and Non-Coding RNAs as Liquid Biopsies for the Management of Colorectal Cancer Patients
Lampis, A; Ghidini, M; Ratti, M; Mirchev, MB; Okuducu, AF; et al. (MDPI, 2020-09-01)<jats:p>Circulating tumour DNAs and non-coding RNAs present in body fluids have been under investigation as tools for cancer diagnosis, disease monitoring, and prognosis for many years. These so-called liquid biopsies offer ... -
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
Smyth, EC; Fassan, M; Cunningham, D; Allum, WH; Okines, AFC; et al. (AMER SOC CLINICAL ONCOLOGY, 2016-08-10)PURPOSE: The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with resectable ... -
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
Smyth, EC; Vlachogiannis, G; Hedayat, S; Harbery, A; Hulkki-Wilson, S; et al. (BMJ PUBLISHING GROUP, 2020-11-16)OBJECTIVE: Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome ... -
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.
Khan, K; Rata, M; Cunningham, D; Koh, D-M; Tunariu, N; et al. (BMJ PUBLISHING GROUP, 2018-08-01)OBJECTIVE: Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better ... -
Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer.
Ghidini, M; Lampis, A; Mirchev, MB; Okuducu, AF; Ratti, M; et al. (MDPI, 2020-12-29)Pancreatic cancer is one of the most aggressive malignancies with limited treatment options thus resulting in high morbidity and mortality. Among all cancers, with a five-year survival rates of only 2-9%, pancreatic cancer ... -
Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas.
Angerilli, V; Fontana, E; Lonardi, S; Sbaraglia, M; Borelli, B; et al. (ELSEVIER, 2021-08-01)BACKGROUND: Intratumor heterogeneity (ITH) is described as the presence of various clones within one tumor, each with their own unique features in terms of morphology, inflammation, genetics or transcriptomics. Heterogeneity ... -
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.
Sclafani, F; Chau, I; Cunningham, D; Hahne, JC; Vlachogiannis, G; et al. (NATURE PORTFOLIO, 2018-01-23)There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples ... -
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.
Khan, KH; Cunningham, D; Werner, B; Vlachogiannis, G; Spiteri, I; et al. (AMER ASSOC CANCER RESEARCH, 2018-08-30)Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection of patient progression. However, how to exploit the predictive power of cfDNA as a liquid biopsy in the clinic remains unclear. ... -
MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma.
Trevisani, F; Ghidini, M; Larcher, A; Lampis, A; Lote, H; et al. (SPRINGERNATURE, 2016-11-01)BACKGROUND: A significant proportion of patients undergoing radical nephrectomy (RN) for clear-cell renal cell carcinoma (RCC) develop chronic kidney disease (CKD) within a few years following surgery. Chronic kidney disease ... -
MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside.
Ratti, M; Lampis, A; Ghidini, M; Salati, M; Mirchev, MB; et al. (SPRINGER, 2020-06-01)Non-coding RNAs represent a significant proportion of the human genome. After having been considered as 'junk' for a long time, non-coding RNAs are now well established as playing important roles in maintaining cellular ... -
MicroRNAs as mediators of drug resistance mechanisms.
Lampis, A; Hahne, JC; Hedayat, S; Valeri, N (ELSEVIER SCI LTD, 2020-10-01)MicroRNAs are small RNA transcripts involved in fine-tuning of several cellular mechanisms and pathways crucial for maintaining cells' homeostasis like apoptosis, differentiation, inflammation and cell-cycle regulation. ... -
MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.
Ghidini, M; Hahne, JC; Frizziero, M; Tomasello, G; Trevisani, F; et al. (SPRINGER, 2018-08-01)Receptor tyrosine kinases (RTKs) are widely expressed transmembrane proteins that act as receptors for growth factors and other extracellular signalling molecules. Upon ligand binding, RTKs activate intracellular signalling ... -
Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.
Ratti, M; Lampis, A; Hahne, JC; Passalacqua, R; Valeri, N (SPRINGER BASEL AG, 2018-11-01)Gastric cancer is one of the most aggressive malignancies, with limited treatment options in both locally advanced and metastatic setting, resulting in poor prognosis. Based on genomic characterization, stomach tumour has ... -
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial.
Anandappa, G; Lampis, A; Cunningham, D; Khan, KH; Kouvelakis, K; et al. (AMER ASSOC CANCER RESEARCH, 2019-07-01)PURPOSE: Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC) patients. RAS status and tumor location (sidedness) are predictive markers of patients' response to anti-EGFR mAbs. Recently, ...